$SCRC ScripsAmerica Enters Supply Agreement With R
Post# of 99168
Posted On: 06/09/2014 9:32:54 AM
$SCRC ScripsAmerica Enters Supply Agreement With RapiMed(R) Manufacturer
Company Formalizes Relationship With RapiMed(R) Supplier Following the Completion of Its First Product Order for Hong Kong
TYSONS CORNER, VA, Jun 09, 2014 (Marketwired via COMTEX) -- ScripsAmerica Inc. (OTCBB: SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced that the Company has signed a 2-year manufacturing supply agreement with the manufacturer of its RapiMed(R) children's pain reliever and fever reducer.
The recently signed agreement formalizes the working relationship between ScripsAmerica and RapiMed(R)'s manufacturer. The two companies have been working together and just completed ScripsAmerica's first order ticketed for Hong Kong in the amount of $200,000.
"Our first RapiMed(R) order took longer to produce since Scrips was contracted for a finished product in the Hong Kong approved packaging which was delivered by our supplier. Subsequent orders will be produced in as little as two weeks from the time they are ordered and we anticipate sales of our first product, RapiMed(R), to increase during the second half of 2014," commented ScripsAmerica's CEO, Bob Schneiderman.
ScripsAmerica has filed an 8-K with the SEC requesting that disclosing the name of the Company's RapiMed(R) manufacturer be considered as "Disclosure of the Confidential Information" and would seriously harm the Company's competitive advantage in China for its product and ability to secure future manufacturing and supply agreements for RapiMed(R) or other orally disintegrating tablet products on terms more advantageous than the Supply Agreement.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Seal Point Consulting
888-959-7095
Company Formalizes Relationship With RapiMed(R) Supplier Following the Completion of Its First Product Order for Hong Kong
TYSONS CORNER, VA, Jun 09, 2014 (Marketwired via COMTEX) -- ScripsAmerica Inc. (OTCBB: SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced that the Company has signed a 2-year manufacturing supply agreement with the manufacturer of its RapiMed(R) children's pain reliever and fever reducer.
The recently signed agreement formalizes the working relationship between ScripsAmerica and RapiMed(R)'s manufacturer. The two companies have been working together and just completed ScripsAmerica's first order ticketed for Hong Kong in the amount of $200,000.
"Our first RapiMed(R) order took longer to produce since Scrips was contracted for a finished product in the Hong Kong approved packaging which was delivered by our supplier. Subsequent orders will be produced in as little as two weeks from the time they are ordered and we anticipate sales of our first product, RapiMed(R), to increase during the second half of 2014," commented ScripsAmerica's CEO, Bob Schneiderman.
ScripsAmerica has filed an 8-K with the SEC requesting that disclosing the name of the Company's RapiMed(R) manufacturer be considered as "Disclosure of the Confidential Information" and would seriously harm the Company's competitive advantage in China for its product and ability to secure future manufacturing and supply agreements for RapiMed(R) or other orally disintegrating tablet products on terms more advantageous than the Supply Agreement.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Seal Point Consulting
888-959-7095
(0)
(0)